Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)

This is an open-label, multicenter international trial in men and women with primary operable HR+/HER2-, ki67≥20%, grade 2 or 3 and stage II breast cancer to evaluate safety and long-term efficacy of a non-chemo treatment in patients biologically responders to neoadjuvant ribociclib and letrozole. This study aims to evaluate whether …

  • 0 views
  • 17 Jun, 2022
  • 11 locations
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA

luteinizing hormone-releasing hormone agonist
gonadotropin
immunological adjuvant
neutrophil count
androgens
  • 72 views
  • 09 May, 2022
  • 63 locations
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as

  • 5 views
  • 06 Jul, 2022
  • 75 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

hormone-releasing hormone) agonist by injection. It is standard of care for people with hormone receptor positive breast cancer to take anti-hormone therapy. The study doctor will determine the

invasive breast cancer
estrogen
aromatase inhibitor
fulvestrant
exemestane
  • 2 views
  • 19 Feb, 2022
  • 55 locations
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

erbb2
progesterone
HER2
tamoxifen
progesterone receptor
  • 90 views
  • 30 Apr, 2022
  • 49 locations
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver

vitamin
cancer
proton magnetic resonance spectroscopy
fatty liver
MRI
  • 3 views
  • 18 Feb, 2022
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients (BonEnza)

This study was undertaken to evaluate bone response in metastatic prostate cancer patients treated with Enzalutamide with or without Zoledronic Acid in combination with luteinizing hormone

prostate carcinoma
gonadotropin
gonadorelin
cancer
metastatic prostate cancer
  • 109 views
  • 02 Mar, 2022
  • 1 location
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: LHRHA (luteinizing hormone

luteinizing hormone-releasing hormone agonist
neutrophil count
apalutamide
growth factor
gonadorelin
  • 5 views
  • 20 Feb, 2022
  • 5 locations
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS)

participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy

  • 0 views
  • 05 Jun, 2022
  • 2 locations
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer (PROMPT)

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the …

gonadotropin
immunological adjuvant
bone scan
metastasis
digital rectal examination
  • 3 views
  • 25 Feb, 2022
  • 2 locations